ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs.

Pulmonary hypertension (PH), defined by increased pressure within the pulmonary vasculature, is a hemodynamic and pathophysiologic state present in a wide variety of cardiovascular, respiratory, and systemic diseases. The purpose of this consensus statement is to provide a multidisciplinary approach to guidelines for the diagnosis, classification, treatment, and monitoring of PH in dogs. Comprehensive evaluation including consideration of signalment, clinical signs, echocardiographic parameters, and results of other diagnostic tests supports the diagnosis of PH and allows identification of associated underlying conditions. Dogs with PH can be classified into the following 6 groups: group 1, pulmonary arterial hypertension; group 2, left heart disease; group 3, respiratory disease/hypoxia; group 4, pulmonary emboli/pulmonary thrombi/pulmonary thromboemboli; group 5, parasitic disease (Dirofilaria and Angiostrongylus); and group 6, disorders that are multifactorial or with unclear mechanisms. The approach to treatment of PH focuses on strategies to decrease the risk of progression, complications, or both, recommendations to target underlying diseases or factors contributing to PH, and PH-specific treatments. Dogs with PH should be monitored for improvement, static condition, or progression, and any identified underlying disorder should be addressed and monitored simultaneously

American College of Veterinary Emergency and Critical Care (ACVECC) Consensus on the Rational use of Antithrombotics in Veterinary Critical Care (CURATIVE) Guidelines: Small Animal

Objectives To systematically review available evidence and establish guidelines related to the risk of developing thrombosis and the management of small animals with antithrombotics. Design Standardized, systematic evaluation of the literature (identified by searching Medline via PubMed and CAB abstracts) was carried out in 5 domains (Defining populations at risk; Defining rational therapeutic use; Defining evidence‐based protocols; Refining and monitoring antithrombotic therapies; and Discontinuing antithrombotic therapies). Evidence evaluation was carried out using Population, Intervention, Comparison, Outcome generated within each domain questions to address specific aims. This was followed by categorization of relevant articles according to level of evidence and quality (Good, Fair, or Poor). Synthesis of these data led to the development of a series of statements. Consensus on the final guidelines was achieved via Delphi‐style surveys. Draft recommendations were presented at 2 international veterinary conferences and made available for community assessment, review, and comment prior to final revisions and publication. Settings Academic and referral veterinary medical centers. Results Over 500 studies were reviewed in detail. Worksheets from all 5 domains generated 59 statements with 83 guideline recommendations that were refined during 3 rounds of Delphi surveys. A high degree of consensus was reached across all guideline recommendations. Conclusions Overall, systematic evidence evaluations yielded more than 80 recommendations for the treatment of small animals with or at risk of developing thrombosis. Numerous significant knowledge gaps were highlighted by the evidence reviews undertaken, indicating the need for substantial additional research in this field

Clinical Application of the American College of Veterinary Emergency and Critical Care (ACVECC) Consensus on the Rational use of Antithrombotics in Veterinary Critical Care (CURATIVE) Guidelines to Small Animal Cases

Objective To illustrate the application of the Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE) guidelines to the management of dogs and cats at risk of developing thrombosis using a case‐based approach. Etiology Dogs and cats become at risk of developing thrombosis from a wide range of conditions. These conditions often involve a specific insult followed by an inflammatory response and when combined with other contributing factors (eg, hypercoagulability, vascular endothelial injury, hemodynamic changes) create favorable conditions for thrombosis. Diagnosis Development of thrombosis in small animals remains challenging to demonstrate. Compatible clinical signs, the presence of known risk factors, and supporting diagnostic tests may be highly suggestive of the development of thrombosis. Therapy Therapeutic recommendations in accordance with the CURATIVE guidelines for dogs and cats are described in specific case vignettes presented. Discussion is centered on antithrombotic drug choices and dosing protocols, as outlined in Domains 2 and 3 of the CURATIVE guidelines. Where appropriate, guidelines related to therapeutic monitoring (Domain 4) and discontinuation of antithrombotics (Domain 5) were included. Prognosis In small animals at risk of developing thrombosis, overall prognosis may be improved by following consensus‐based recommendations on the use of antithrombotics as outlined in the CURATIVE guidelines. Whether such interventions have any impact on outcome requires further investigation

2022 Update of the consensus on the rational use of antithrombotics and thrombolytics in Veterinary Critical Care (CURATIVE) Domain 1‐ Defining populations at risk

Objectives To expand the number of conditions and interventions explored for their associations with thrombosis in the veterinary literature and to provide the basis for prescribing recommendations. Design A population exposure comparison outcome format was used to represent patient, exposure, comparison, and outcome. Population Exposure Comparison Outcome questions were distributed to worksheet authors who performed comprehensive searches, summarized the evidence, and created guideline recommendations that were reviewed by domain chairs. The revised guidelines then underwent the Delphi survey process to reach consensus on the final guidelines. Diseases evaluated in this iteration included heartworm disease (dogs and cats), immune-mediated hemolytic anemia (cats), protein-losing nephropathy (cats), protein-losing enteropathy (dogs and cats), sepsis (cats), hyperadrenocorticism (cats), liver disease (dogs), congenital portosystemic shunts (dogs and cats) and the following interventions: IV catheters (dogs and cats), arterial catheters (dogs and cats), vascular access ports (dogs and cats), extracorporeal circuits (dogs and cats) and transvenous pacemakers (dogs and cats). Results Of the diseases evaluated in this iteration, a high risk for thrombosis was defined as heartworm disease or protein-losing enteropathy. Low risk for thrombosis was defined as dogs with liver disease, cats with immune-mediated hemolytic anemia, protein-losing nephropathy, sepsis, or hyperadrenocorticism. Conclusions Associations with thrombosis are outlined for various conditions and interventions and provide the basis for management recommendations. Numerous knowledge gaps were identified that represent opportunities for future studies

2022 Update of the consensus on the rational use of antithrombotics and thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics

Objectives To systematically review available evidence and establish guidelines related to the use of thrombolytics for the management of small animals with suspected or confirmed thrombosis. Design PICO (Population, Intervention, Control, and Outcome) questions were formulated, and worksheets completed as part of a standardized and systematic literature evaluation. The population of interest included dogs and cats (considered separately) and arterial and venous thrombosis. The interventions assessed were the use of thrombolytics, compared to no thrombolytics, with or without anticoagulants or antiplatelet agents. Specific protocols for recombinant tissue plasminogen activator were also evaluated. Outcomes assessed included efficacy and safety. Relevant articles were categorized according to level of evidence, quality, and as to whether they supported, were neutral to, or opposed the PICO questions. Conclusions from the PICO worksheets were used to draft guidelines, which were subsequently refined via Delphi surveys undertaken by the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) working group. Results Fourteen PICO questions were developed, generating 14 guidelines. The majority of the literature addressing the PICO questions in dogs is experimental studies (level of evidence 3), thus providing insufficient evidence to determine if thrombolysis improves patient-centered outcomes. In cats, literature was more limited and often neutral to the PICO questions, precluding strong evidence-based recommendations for thrombolytic use. Rather, for both species, suggestions are made regarding considerations for when thrombolytic drugs may be considered, the combination of thrombolytics with anticoagulant or antiplatelet drugs, and the choice of thrombolytic agent. Conclusions Substantial additional research is needed to address the role of thrombolytics for the treatment of arterial and venous thrombosis in dogs and cats. Clinical trials with patient-centered outcomes will be most valuable for addressing knowledge gaps in the field

Efficacy of flumioxazin applied alone and in a tank mix with diuron or diclosulam added with different adjuvants in cotton

O objetivo da presente pesquisa foi avaliar a eficácia e seletividade do herbicida flumioxazin aplicado em pós-emergência isoladamente e na mistura em tanque com diuron ou diclosulam, na cultura do algodão. Adotou-se o delineamento de blocos ao acaso, com quatro repetições. Foram estudados os seguintes tratamentos: flumioxazin a 30 g/ha, flumioxazin+diuron (25+800 e 25+1000 g/ha), flumioxazin+diclos~lam (25+30 e 25+35 g/ha), MSMA+diuron (1800+1000 glha) como tratamento padrão, além de duas testemunhas, uma capinada e outra infestada, para as comparações nas avaliações de fitotoxicidade e de controle, respectivamente. Aos herbicidas adicionou-se óleo mineral Assist a 0,5% v/vou Triomax a 0,25% v/v como adjuvantes. O efeito dos herbicidas foi avaliado aos 25 e 39 dias após a aplicação (DAA) e a fito intoxicação aos 10 e 25 DAA. As espécies Commelina benghalensis (trapoeraba), Ipomoea grandifolia (corda-de-viola) e Raphanus raphanistrum (nabiça) foram controladas eficientemente pelo herbicida flumioxazin, isoladamente ou em mistura com diuron ou diclosulam até 39 DAA, com comportamento semelhante ao constatado para o tratamento padrão.lNão foram observadas diferenças significativas na produção entre os tratamentos com herbicidas e deles com a testemunha capinada. As plantas de algodão (cv. Coodetec 401) apresentaram leves sintomas de injúrias por ação fitotóxica dos produtos químicos, nos tratamentos envolvendo flumioxazin em mistura com diuron na maior dose e com diclosulam em ambas as doses, porém com rápida e plena recuperação, sem afetar o rendimento da cultura. A field experiment was carried out in Itapira, SP, to evaluate the selectivity and efficiency ofthe herbicide flumioxazin alone or in a tank mix with diuron or diclosulam applied in post-ernergence to weed control in cotton cv. Coodetec 40 I,with two different mineral oils. The experimental design was a randomized block with four replications and the foIlowing treatments: flumioxazin (30 g/ha), flumioxazin+diuron (25+800 and 25+ 1,000 g/ha), flumioxazin+diclosulam (25+30 and 25+35 g/ha), MSMA+diuron (1,800+1,000 g/ha) with standard treatrnent and controls with and without weeds. The adjuvants used were Assist at 0,5% v/v and Triomax at 0,25% v/v. The results showed that flumioxazin herbicide alone or in a tank mix with diuron or diclosulam have controIled efficiently Commelina benghalensis L., lpomoea grandifolia (Dammer) O'Don. and Raphanus raphanistrum L. until 39 days afie r the post-emergence application. The two adjuvants had no significant effect on the results. None of the chemical treatments affected the cotton plant development or yield.

Stars, Star Clusters, and Dust in NGC 3077

Images obtained with the CFHTIR camera on the Canada-France-Hawaii Telescope are used to investigate the near-infrared photometric properties of the star-forming M81 group galaxy NGC 3077. The spectral-energy distribution (SED) of the near-infrared light within 10 arcsec of the nucleus is consistent with the 2um light being dominated by hot young (log(t_{yr}) < 6.8) stars reddened by A_V = 3 - 4, with A_V < 8 mag in some regions. A population like that near the center of NGC 205 likely contributes only a modest fraction of the light near 2um. A number of candidate star clusters are detected in and around NGC 3077. The specific frequency of globular clusters falls within the range measured in nearby dEs. The candidate young clusters have photometric masses that are similar to those of compact young clusters in other active star-forming systems, and SEDs consistent with ages log(t_{yr}) < 6.6. Based on the masses and ages of the young clusters, it is estimated that the star formation rate in NGC 3077 was at least 0.25 - 0.50 solar masses per year during the past few million years.Comment: 26 pages + 7 postscript figures; to appear in the Astronomical Journa